Hutchmed Limited

Lung cancer, a leading cause of cancer death globally, affects 2.4 million annually. TAGRISSO (osimertinib), a third-generation EGFR-TKI, is pivotal in treating EGFRm NSCLC, with extensive evidence supporting its use across various stages. AstraZeneca continues to innovate in lung cancer treatment, aiming to improve outcomes and redefine care.

Takeda secures Japanese MHLW approval for FRUZAQLA capsules to treat advanced or recurrent colorectal cancer, based on FRESCO-2 trial results showing significant improvement in overall survival and progression-free survival.

HUTCHMED announces Takeda's approval from Japan's MHLW to manufacture and market FRUZAQLA® (fruquintinib) for previously treated metastatic colorectal cancer (CRC), marking the first novel targeted therapy approved in Japan for metastatic CRC in over a decade. CRC is the most prevalent cancer in Japan, with an estimated 161,000 new cases and 54,000 deaths in 2023. The approval was based on results from the global Phase III FRESCO-2 trial. Fruquintinib is already approved in the United States, Europe, and China.

TROPION-Lung01 trial results show datopotamab deruxtecan (12.9 months OS) vs. docetaxel (11.8 months OS) in overall population, with nonsquamous histology showing 14.6 months vs. 12.3 months OS. In patients with actionable genomic alterations, datopotamab deruxtecan showed 15.6 months OS compared to 9.8 months with docetaxel. NeoCOAST-2 trial preliminary results indicate 34.1% pCR and 65.9% mPR with datopotamab deruxtecan plus Imfinzi and carboplatin in early-stage NSCLC.